p-Synephrine and its various pharmacological effects

Wojciech Ziemichod; Ewa Gibula-Tarlowska; Jolanta H. Kotlinska; Pawel Grochecki; Ewa Kedzierska

doi:10.2478/cipms-2021-0031

.blurhash-client-img { display: none !important; }

p-Synephrine and its various pharmacological effects

Current Issues in Pharmacy and Medical Sciences

Volume 34 (2021): Issue 4 (December 2021)

By: Wojciech Ziemichod , Ewa Gibula-Tarlowska , Jolanta H. Kotlinska , Pawel Grochecki and Ewa Kedzierska

Open Access

|Dec 2021

Abstract

There is a number of diseases for which, scientists are constantly looking for a promising new treatments. Isolation of novel substances with biological activity from plants gives hope for its use in treatment. In this review, we focused on the biological activity of p-synephrine (4-(2-aminoethyl)phenol) which was previously confirmed during both in vitro and in vivo tests. The main part of the review is dedicated to the anti-obesity activity of p-synephrine, as obesity is a disease of contemporary civilization. However, synephrine also possesses anti-diabetic, anti-inflammatory and antidepressant activity and it is confirmed to be a hypotensive agent in portal hypertension. The review also emphasize that, based on current knowledge, the use of p-synephrine appears to be exceedingly safe with only limited range of side effects. Therefore, it seems that this substance may be of great importance in the pharmacotherapy of many disease states and further research is necessary.

References

1. Wang R, Wan L, Li Q, Liu X, Huang Y. Chemiluminescence of synephrine based on the cerium(IV) – rhodamine B system. Luminescence. 2007;22(2):140-6.10.1002/bio.937
Open DOI Search in Google Scholar Back to article
2. Watson DG, Midgley JM, Chen RN, Huang W, Bain GM, McDonald NM, et al. Analysis of biogenic amines and their metabolites in biological tissues and fluids by gas chromatography - negative ion chemical ionization mass spectrometry (GC-NICIMS). J Pharm Biomed Anal. 1990;8(8-12):899-904.10.1016/0731-7085(90)80139-G
Open DOI Search in Google Scholar Back to article
3. Stohs SJ. Safety, Efficacy, and Mechanistic Studies Regarding Citrus aurantium (Bitter Orange) Extract and p-Synephrine. Phytother Res. 2017;31(10):1463-74.10.1002/ptr.5879
Open DOI Search in Google Scholar Back to article
4. Rossato LG, Costa VM, Limberger RP, Bastos Mde L, Remião F. Synephrine: from trace concentrations to massive consumption in weight-loss. Food Chem Toxicol. 2011;49(1):8-16.10.1016/j.fct.2010.11.007
Open DOI Search in Google Scholar Back to article
5. Xu WW, Zheng C, Huang Y, Chen W, Yang Q, Ren J, et al. Synephrine hydrochloride suppresses esophageal cancer tumor growth and metastatic potential through inhibition of Galectin-3-AKT/ERK signaling. Agric Food Chem. 2018;66(35):9248-58.10.1021/acs.jafc.8b04020
Open DOI Search in Google Scholar Back to article
6. Roh K, Kim I, Kim Y, Lee M, Lee J, Jung E, et al. Synephrine inhibits eotaxin-1 expression via the STAT6 signaling pathway. Molecules. 2014;19(8):11883-95.10.3390/molecules190811883
Open DOI Search in Google Scholar Back to article
7. Wu Q, Li R, Soromou LW, Chen N, Yuan X, Sun G, et al. p-Synephrine suppresses lipopolysaccharide-induced acute lung injury by inhibition of the NF-κB signaling pathway. Inflamm Res. 2014; 63(6):429-39.10.1007/s00011-014-0715-7
Open DOI Search in Google Scholar Back to article
8. Kim KW, Kim HD, Jung JS, Woo RS, Kim HS, Suh HW, et al. Characterization of antidepressant-like effects of p-synephrine stereoisomers. Naunyn Schmiedebergs Arch Pharmacol. 2001;364(1): 21-26.10.1007/s002100100416
Open DOI Search in Google Scholar Back to article
9. Magos GA, Vidrio H, Reynolds WF, Enriguez RG. Pharmacology of Casimiroa edulis IV. Hypotensive effects of compounds isolated from methanolic extracts in rats and guinea pigs. J Ethnopharmacol. 1999;64(1):35-44.10.1016/S0378-8741(98)00101-9
Open DOI Search in Google Scholar Back to article
10. Hibino T, Yuzurihara M, Kase Y, Tekeda A. Synephrine, a component of evodiae fructus, constricts isolated rat aorta via adrenergic and serotonergic receptors. J Pharmacol Sci. 2009;111(1):73-81.10.1254/jphs.09077FP19721332
Open DOI Search in Google Scholar Open in PubMed Back to article
11. Huang YT, Lin HC, Chang YY, Yang YY, Lee SD, Hong CY. Hemodynamic effects of synephrine treatment in portal hypertensive rats. Jpn J Pharmacol. 2001;85(2):183-8.10.1254/jjp.85.18311286401
Open DOI Search in Google Scholar Open in PubMed Back to article
12. Stohs SJ, Shara M, Ray SD. p-Synephrine, ephedrine, p-octopamine and m-synephrine: Comparative mechanistic, physiological and pharmacological properties. Phytother Res. 2020;34(8):1838-46.10.1002/ptr.6649749638732101364
Open DOI Search in Google Scholar Open in PubMed Back to article
13. Hong NY, Cui ZG, Kang HK, Lee DH, Lee YK, Park DB. p-Synephrine stimulates glucose consumption via AMPK in L6 skeletal muscle cells. Biochem Biophys Res Commun. 2012;418(4):720-4.10.1016/j.bbrc.2012.01.08522306011
Open DOI Search in Google Scholar Open in PubMed Back to article
14. Brown CM, McGrath JC, Midgley JM, Muir AG, O’Brien JW, Thonoor CM, et al. Activities of octopamine and synephrine stereoisomers on α-adrenoreceptors. Br J Pharmacol. 1988;93(2): 417-29.10.1111/j.1476-5381.1988.tb11449.x18538042833972
Open DOI Search in Google Scholar Open in PubMed Back to article
15. Takagi M, Kimura K, Nakashima KI, Hirai T, Inoue M. Induction of beige adipocytes by naturally occurring β3-adrenoceptor agonist p-synephrine. Eur J Pharmacol. 2018;836:67-74.10.1016/j.ejphar.2018.08.01130120922
Open DOI Search in Google Scholar Open in PubMed Back to article
16. Shara M, Stohs SJ, Smadi, MM. Safety evaluation of p-synephrine following 15 days of oral administration to healthy subjects. A clinical study. Phytother Res. 2018;32(1):125-31.10.1002/ptr.595629130542
Open DOI Search in Google Scholar Open in PubMed Back to article
17. Cui Z, Lee Y, Lee Y, Park D. p-Synephrine suppresses glucose production but not lipid accumulation in H4IIE liver cells. J Med Food. 2015;18(1):76-82.10.1089/jmf.2013.3133428183825379695
Open DOI Search in Google Scholar Open in PubMed Back to article
18. Stohs SJ, Badmaev V. A review of natural stimulant and non-stimulant thermogenic agents. Phytother Res. 2016;30(5):732-40.10.1002/ptr.5583506754826856274
Open DOI Search in Google Scholar Open in PubMed Back to article
19. Maldonado MR, Bracht L, de Sá-Nakanishi AB, Correa RCG, Comar JF, Peralta RM, et. al. Actions of p-synephrine on hepatic enzyme activities linked to carbohydrate metabolism and ATP levels in vivo and in the perfused rat liver. Cell Biochem Funct. 2018;36(1):4-12.10.1002/cbf.331129270996
Open DOI Search in Google Scholar Open in PubMed Back to article
20. Taslimi P, Akıncıoglu H, Gülçin İ. Synephrine and phenylephrine act as α-Amylase, α-Glycosidase, acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase enzymes inhibitors. J Biochem Mol Toxicol. 2017;31(11).10.1002/jbt.2197328800181
Open DOI Search in Google Scholar Open in PubMed Back to article
21. Gutiérrez-Hellín J, Del Coso J. Effects of p-Synephrine and caffeine ingestion on substrate oxidation during exercise. Med Sci Sports Exerc. 2018;50(9):1899-906.10.1249/MSS.000000000000165329727404
Open DOI Search in Google Scholar Open in PubMed Back to article
22. Guo LX, Chen G, Yin ZY, Zhang YH, Zheng XX. p-Synephrine exhibits anti-adipogenic activity by activating the Akt/GSK3β signaling pathway in 3T3-L1 adipocytes. J Food Biochem. 2019;43(11).10.1111/jfbc.1303331486092
Open DOI Search in Google Scholar Open in PubMed Back to article
23. Haaz S, Fontaine KR, Cutter G, Limdi N, Perumean-Chaney S, Allison DB. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Rev. 2006;7(1):79-88.10.1111/j.1467-789X.2006.00195.x16436104
Open DOI Search in Google Scholar Open in PubMed Back to article
24. Zheng X, Guo L, Wang D, Deng X. p-Synephrine: a novel agonist for neuromedin U2 receptor. Biol Pharm Bull. 2014;37(5):764-70.10.1248/bpb.b13-0078824598981
Open DOI Search in Google Scholar Open in PubMed Back to article
25. de Oliveira AL, Comar JF, de Sá-Nakanishi AB, Peralta RM, Bracht A. The action of p-synephrine on hepatic carbohydrate metabolism and respiration occurs via both Ca²⁺ –mobilization and cAMP production. Mol Cell Biochem. 2014;388(1-2):135-47.10.1007/s11010-013-1905-224287564
Open DOI Search in Google Scholar Open in PubMed Back to article
26. Stohs SJ, Preuss HG, Keith SC, et al. Effects of p-synephrine alone and in combination with selected bioflavonoids on resting metabolism, blood pressure, heart rate and self-reported mood changes. Int J Med Sci. 2011;8(4):295-301.10.7150/ijms.8.295308517621537493
Open DOI Search in Google Scholar Open in PubMed Back to article
27. Stohs SJ, Preuss HG, Shara M. A review of the human clinical studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p-synephrine. Int J Med Sci. 2012;9(7):527-38.10.7150/ijms.4446344497322991491
Open DOI Search in Google Scholar Open in PubMed Back to article
28. Stohs SJ, Preuss HG, Shara M. The Safety of Citrus aurantium (Bitter Orange) and its Primary Protoalkaloid p-Synephrine. Phytother Res. 2011;25(10):1421-8.10.1002/ptr.349021480414
Open DOI Search in Google Scholar Open in PubMed Back to article
29. Wierzejska R. Dietary supplements – panacea to contemporary health problems, or the triumph of advertisement? Med Rodz. 2017; 20(2):136-42.
Search in Google Scholar Back to article
30. Mercader J, Wanecq E, Chen J, Carpene C. Isopropylnorsynephrine is a stronger lipolytic agent in human adipocytes than synephrine and other amines present in Citrus aurantium. J Physiol Biochem. 2011;67(3):443-52.10.1007/s13105-011-0078-221336650
Open DOI Search in Google Scholar Open in PubMed Back to article
31. Arbo MD, Schmitt GC, Limberger MF, Charão MF, Moro AM, Ribeiro GL, et al. Subchronic toxicity of Citrus aurantium L. (Rutaceae) extract and p-synephrine in mice. Regul Toxicol Pharmacol. 2009;54(2);114-7.10.1016/j.yrtph.2009.03.00119275924
Open DOI Search in Google Scholar Open in PubMed Back to article
32. Song DK, Suh HW, Jung JS, Wie MB, Son KH, Kim YH. Antidepressant-like effects of p-synephrine in mouse models of immobility tests. Neurosci Lett. 1996;214(2-3):107-10.10.1016/0304-3940(96)12895-0
Open DOI Search in Google Scholar Back to article
33. Deshmukh NS, Stohs SJ, Magar CC, Kadam SB. Citrus aurantium (bitter orange) extract: Safety assessment by acute and 14-day oral toxicity studies in rats and the Ames Test for mutagenicity. Regul Toxicol Pharmacol. 2017;90:318-27.10.1016/j.yrtph.2017.09.02728966104
Open DOI Search in Google Scholar Open in PubMed Back to article

Articles in this issue

DOI: https://doi.org/10.2478/cipms-2021-0031 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X

Journal RSS Feed

Language: English

Page range: 169 - 173

Submitted on: Jul 19, 2021

Accepted on: Sep 17, 2021

Published online: Dec 30, 2021

Published in print: Dec 1, 2021

Published by: Sciendo

In partnership with: Paradigm Publishing Services

Keywords:

p-synephrine,

anti-obesity activity,

anti-diabetic activity,

anti-inflammatory activity,

antidepressant activity

Related subjects:

Medicine,

Clinical medicine,

Pharmacology, toxicology

© 2021 Wojciech Ziemichod, Ewa Gibula-Tarlowska, Jolanta H. Kotlinska, Pawel Grochecki, Ewa Kedzierska, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 34 (2021): Issue 4 (December 2021)